Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Alan Brezin who wrote (2727)	10/7/1999 2:10:00 PM
From: BostonView	Respond to of 2836

The mountain is rumbling again today...quarterly spike time? BV

To: Alan Brezin who wrote (2727)	10/19/1999 10:30:00 AM
From: Toni Wheeler	Read Replies (1) \| Respond to of 2836

Sense it does make, YES, Alan, This is VERY encouraging this morning: CEL-SCI Reports Encouraging Clinical Findings in HIV-Infected Patients VIENNA, Va., Oct. 19 /PRNewswire/ -- CEL-SCI Corporation (Amex: HIV; Berlin Stock Exchange:LSR) announced today that independent investigators at AIDS ReSEARCH Alliance, West Hollywood, California, have completed a clinical study using CEL-SCI's Multikine(TM) to determine primarily its safety, and secondarily its ability to improve the immune function of HIV-infected patients. The investigators concluded that, given the safety, low side effect profile and the improved cell-mediated immunity (CMI) responses to several test recall antigens, Multikine should be pursued with a larger follow-on, placebo-controlled study. The investigators at AIDS ReSEARCH Alliance, Stephen J. Brown, M.D. and George Fareed, M.D., studied 14 patients in an open-label study using two doses of Multikine. The patients were HIV-1 infected, treated with concomitant HAART (Highly Active Anti-Retroviral Therapy), had CD4+ counts in excess of 500 and a viral load of less than 50,000 copies/ml by PCR. Multikine was self-administered subcutaneously 5 times a week for 8 weeks. The patients were followed through week 12. Preliminary findings indicated Multikine to be both safe and well- tolerated. The key finding in this study, other than safety, was that some patients showed an increased ability to respond to several recall antigens, such as Tetanus toxoid, Candida antigen and Proteus antigen. Restoration of immune response to recall antigens suggests an improved cellular immunity and ability to resist opportunistic infections, such as candidiasis (oral thrush). HIV-infected patients generally lose their capacity to respond to recall antigens. The results of this small trial suggest that Multikine treatment may be useful in lowering the incidence and/or lessening the severity of opportunistic infections in HIV-infected patients. However, as the investigators have recommended, larger studies are needed to confirm these preliminary findings. Further details will be presented at a scientific conference and submitted for publication. Multikine is a mixture of naturally occurring immune system regulators called cytokines. One of these cytokines, Interleukin-2, is currently being tested as an immune booster in HIV-infected patients. Multikine has been tested in over 100 patients and is currently in several phase II trials in 6 countries against head and neck cancer. CEL-SCI Corporation is a biopharmaceutical company whose mission it is to mobilize the immune system to combat disease. "CEL-SCI press releases are available through Company News On-Call by fax, (800) 758-5804, Ext. 445563, or at cel-sci.com on the Internet." When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1998. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. ------------------------------------------------------------------------ SOURCE: ÿCEL-SCI Corporation CONTACT: ÿMedia Contact: Geert Kersten, Chief Executive Officer of CEL- SCI Corporation, 703-506-9460; or Investor Relations: Daryll Strahl, 970-377-2216, for CEL-SCI Corporation>>>